Mohsin Farhan, Wyatt Laura, Belli Hayley, Ali Shahmir, Onakomaiya Deborah, Misra Supriya, Yusuf Yousra, Mammen Shinu, Zanowiak Jennifer, Hussain Sarah, Zafar Haroon, Lim Sahnah, Islam Nadia, Ahmed Naheed
Institute for Excellence in Health Equity, NYU Grossman School of Medicine, 180 Madison Ave, New York, NY, 10016, USA.
Department of Population Health, NYU Grossman School of Medicine, 180 Madison Ave, New York, NY, 10016, USA.
BMC Public Health. 2025 Feb 2;25(1):422. doi: 10.1186/s12889-025-21535-8.
Type 2 diabetes (T2D) disproportionately affects individuals of South Asian descent. Additionally, diabetes distress (DD) may lead to complications with diabetes management. This study examines the prevalence of DD among foreign-born individuals of South Asian descent in New York City (NYC) and its association with sociodemographic and clinical factors.
Baseline data was collected from the Diabetes Research, Education, and Action for Minorities (DREAM) Initiative, an intervention designed to reduce hemoglobin A1c (HbA1c) among South Asian individuals with uncontrolled T2D at primary care practices in NYC. The Diabetes Distress Scale (DDS) measured DD, and Core Healthy Days Measures assessed physical and mental healthy days. Sociodemographic variables were analyzed using descriptive statistics, Chi-square tests assessed categorical variables, and Wilcoxon Rank Sum tests evaluated continuous variables (Type I error rate = 0.05). Logistic regression models examined associations between HbA1c, mental health, and other covariates with dichotomized DD subscales.
Overall, 414 participants completed the DDS at baseline (median age = 55.2 years; SD = 9.8). All were born outside of the US; the majority were born in Bangladesh (69.8%) followed by India, Pakistan, and Nepal (24.7%) and Guyana and Trinidad and Tobago (5.5%). High emotional burden, regimen-related distress and physician-related distress were reported by 25.9%, 21.9%, and 6.2% of participants, respectively. In adjusted analyses, individuals with ≥ 1 day of poor mental health had higher odds of overall distress (OR:3.8, p = 0.013), emotional burden (OR:4.5, p < 0.001), and physician-related distress (OR:4.6, p = 0.007) compared to individuals with no days of poor mental health. Higher HbA1c (OR:1.45, p = < 0.001) was associated with regimen-related distress; and lower emotional support was associated with overall distress (OR:0.92, p < 0.001) and regimen-related distress (OR:0.95, p = 0.012). Individuals born in Bangladesh had significantly lower odds of overall distress, emotional burden, and regimen-related distress compared to individuals born in Guyana and Trinidad and Tobago.
Findings highlight the rate and risk factors of DD among individuals of South Asian descent living in NYC. Screening for DD in patients with prediabetes or diabetes should be integrated to address mental and physical health needs. Future research can benefit from a longitudinal analysis of the impact of DD on diabetes self-management and health outcomes.
This study uses baseline data from "Diabetes Management Intervention for South Asians" (NCT03333044), which was registered with clinicaltrials.gov on 6/11/2017.
2型糖尿病(T2D)对南亚裔个体的影响尤为严重。此外,糖尿病困扰(DD)可能会导致糖尿病管理出现并发症。本研究调查了纽约市(NYC)出生于国外的南亚裔个体中DD的患病率及其与社会人口学和临床因素的关联。
基线数据收集自糖尿病研究、教育与少数族裔行动(DREAM)倡议,这是一项旨在降低纽约市初级医疗诊所中未得到有效控制的T2D南亚个体血红蛋白A1c(HbA1c)水平的干预措施。采用糖尿病困扰量表(DDS)测量DD,核心健康天数指标评估身心健康天数。使用描述性统计分析社会人口学变量,卡方检验评估分类变量,Wilcoxon秩和检验评估连续变量(I型错误率 = 0.05)。逻辑回归模型研究了HbA1c、心理健康及其他协变量与二分法DD子量表之间的关联。
总体而言,414名参与者在基线时完成了DDS(中位年龄 = 55.2岁;标准差 = 9.8)。所有参与者均出生在美国境外;大多数出生在孟加拉国(69.8%),其次是印度、巴基斯坦和尼泊尔(24.7%)以及圭亚那和特立尼达和多巴哥(5.5%)。分别有25.9%、21.9%和6.2%的参与者报告有高情绪负担、治疗方案相关困扰和医生相关困扰。在调整分析中,与心理健康状况良好的个体相比,心理健康状况不佳天数≥1天的个体出现总体困扰(比值比:3.8,p = 0.013)、情绪负担(比值比:4.5,p < 0.001)和医生相关困扰(比值比:4.6,p = 0.007)的几率更高。较高的HbA1c水平(比值比:1.45,p = < 0.001)与治疗方案相关困扰有关;较低的情感支持与总体困扰(比值比:0.92,p < 0.001)和治疗方案相关困扰(比值比:0.95,p = 0.012)有关。与出生在圭亚那和特立尼达和多巴哥的个体相比,出生在孟加拉国的个体出现总体困扰、情绪负担和治疗方案相关困扰的几率显著更低。
研究结果突出了纽约市南亚裔个体中DD的发生率及风险因素。应将对糖尿病前期或糖尿病患者的DD筛查纳入其中,以满足其身心健康需求。未来的研究可通过对DD对糖尿病自我管理和健康结局影响的纵向分析而受益。
本研究使用了“南亚人糖尿病管理干预”(NCT03333044)的基线数据,该研究于2017年6月11日在clinicaltrials.gov上注册。